Our Team of Experts

We are a driven team of specialists, committed to advancing the naturally derived medicine industry. Our team has experience across multiple sectors – pharmaceutical operations, research and development, intellectual property, marketing and finance – and is based in the UK, Europe and North America.

Management & Board


Filipp Korentsvit



Filipp Korentsvit is one of the founding partners of NW PharmaTech.


After university Filipp joined Goldman Sachs in their London office where he worked for 7 years on the Emerging Markets Structuring desk in the Fixed Income division, finally in the role of Executive Director. Filipp left GS to pursue his entrepreneurial ambitions and founded a mining services company in Ulaanbaatar, Mongolia. Most recently prior to establishing NW PharmaTech, Filipp was the financial advisor to an internationally active family office.


Filipp holds a Bachelors of Science degree in Economics and Statistics from the University College London.


Daud Gutseriev



Daud Gutseriev is one of the founding partners of NW PharmaTech.


Prior to establishing NW PharmaTech with his business partners, Daud worked at VTB Capital for over 10 years, most recently as an Associate Director in the Infrastructure Capital & Project Financing team. Daud gained extensive experience in the field of project structuring and in the raising of both debt and equity financing. Daud worked on a number of high profile infrastructure projects in various roles.


Daud holds a Bachelors of Science degree in the field of Management from University of Royal Holloway (University of London) and an Executive MBA from University of Oxford - Saïd Business School.


Max Moldaschl



Maximilian Moldaschl is one of the founding partners of NW PharmaTech.


After working for various leading London based financial institutions for 13 years – most recently as a Director of Global Asset Allocation & Macro Strategy in Citigroup and as a Senior Cross-Asset Strategist in the Multi-Asset funds of BNP Paribas Asset Management – Max left the finance industry to pursue his passion for nature and to apply his skills as an entrepreneur.


Max holds a Masters in Engineering degree with First Class Honours in the field of Aeronautical Engineering from Imperial College London.


William Jarosz

Partner & Executive Chairman of the Board of Directors


William (Bill) Jarosz is a partner at NW PharmaTech and the Executive Chairman of the Board of Directors.


Bill is an accomplished business leader, with a background in both finance and the pharmaceutical sector. He currently is an executive Board Member of Satellos Bioscience Inc., a publicly traded drug discovery company listed on the Toronto Venture Exchange. Bill also serves as President of a Satellos subsidiary specializing in micellization technologies. From 2020-2021, Bill was the Chief Executive Officer of iCo Therapeutics, Inc., where he formulated and led the sale process of iCo to Satellos. Bill is also a Founding Partner of Cartesian Capital Group, a global investment management firm providing growth capital to business worldwide since 2006.


From 1997 until 2005, Bill served as Managing Director and General Counsel of AIG Capital Partners, a subsidiary of American International Group, Inc., and as Managing Director of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr. Jarosz oversaw global private equity transactions for the firm's various private equity funds. Prior to joining AIG in 1997, Mr. Jarosz practiced law at Debevoise & Plimpton, specializing in international private equity investment. Mr. Jarosz also served as a consultant to the World Bank on the regulation of Foreign Direct Investment in emerging markets.


Bill is a graduate of the University of Montana and received an MA in Law and Diplomacy from the Fletcher School at Tufts University and a JD from Harvard Law School.


Professor Richard Barker

Partner & Senior Advisor - Head of Advisory Board


Prof. Richard Barker, BSc, MA, DPhil (Oxon), FRSM, HFBPS, OBE is a senior business and scientific advisor at NW PharmaTech, and heads the advisory board.


Richard is a senior leader in the global life sciences sector. His professional interests focus on innovation and translation in precision medicine & health, drawing on his 30-year career in senior roles in biopharmaceuticals (Director General of the ABPI and NED at Celgene), diagnostics (CEO of Chiron Diagnostics) and medical informatics (Global General Manager of IBM Healthcare). He chaired the Population Health section of the recent UK All-Party Parliamentary Group on Health Longevity.


His other positions include Founder & CEO of New Medicine Partners, Co-Founder of two early-stage businesses, Metadvice (healthcare AI) and Innohealth (Asia/Europe biotech licensing), Chairman of the Health Innovation Network and a Non-Executive Director for the Image Analysis Group. He also holds honorary faculty positions at Oxford University and Kings College London.
Richard has published two Oxford University Press books: ‘2030—the future of medicine’ and ‘Bioscience—lost in translation?’ as well as numerous academic papers.


Advisory Board & Lead Academics


John Smith

Partner & Senior Commercial Advisor


John Smith is the Commercial Advisor of NW PharmaTech.


John is an experience pharma executive, drawing on a 25 year career in senior roles at multi-national pharma corporations.


Prior to joining NW PharmaTech, John was the Chief Executive of the Proprietary Association of Great Britain (PAGB), where he provided leadership and guidance in shaping the UK consumer healthcare industry. John was also the Business Unit Lead UK, Ireland and Netherlands for Pfizer Consumer Healthcare, where he met ambitious P&L objectives, spearheaded long-term strategic growth, organisational and business development. His other positions included General Manager UK & Ireland and General Manager Portugal, Russia, South Africa & Spain for Wyeth Consumer Healthcare.


Wibke Stoffers

Partner and Senior Marketing & Branding Advisor


Wibke Stoffers is the Marketing & Branding Advisor of NW PharmaTech.


Wibke is an experienced Business and Marketing strategist in the Consumer Healthcare industry.


Wibke previously worked as the Regional Marketing and Innovation Director for Europe, Middle East and Africa for Pfizer Consumer Healthcare, and was the Marketing Manager at Energizer Wilkinson Sword.


Wibke holds a Masters Degree in Management from HEC Paris and a Bachelors of Science Degree in Economics and History from UCL London.


Professor Matthew Walker

Partner & Chief Sleep Officer


Professor Matthew Walker is the Chief Sleep Officer at NW PharmaTech.


Matthew is Professor of Neuroscience and Psychology at the University of California, Berkeley, and Founder and Director of the Center for Human Sleep Science.


Matthew’s research examines the impact of sleep on human health and disease. He has received numerous funding awards from the National Science Foundation and the National Institutes of Health, and is a Kavli Fellow of the National Academy of Sciences.
To date, he has published over 100 scientific research studies and has been featured on numerous television and radio outlets, including CBS 60 Minutes, National Geographic Channel, NOVA Science, NRP and the BBC.


Matthew earned his degree in neuroscience from Nottingham University, UK, and his PhD in neurophysiology from the Medical Research Council, London, UK. He subsequently became a Professor of Psychiatry at Harvard Medical School, USA.


Professor Gennady Shvarts

Medical Advisor


Prof. Gennady Shvarts, MD (First Moscow Medical University by I. Sechenov), PhD, Doctor of Science, is the Medical Advisor at NW PharmaTech.


Gennady is a professor of pharmacology with over 40 years professional experience in the field. He specialises in the pharmacology of the Kinin system, Inhibitors of RAS and the development of medicines, screening methodologies, experimental and clinical studies of innovative drugs and generics in the fields NSAID, bronchodilators, antihypertensive, analgesics, and activators of cognitive functions.


Gennady held various senior positions during his career, most recently at Teva Pharmaceutical Ind. Ltd., where between 2002 and 2014 he was the Medical Director of Teva’s Moscow office and from 2014 to present is the Director of Scientific and Medical Affairs.


Throughout his professional career, Gennady has published more than 280 scientific papers; filed 30 patents and most distinctly developed two innovative drugs (Troventol – a broncho-dilating drug, Methiapril – an antihypertensive drug), as well as bringing a range of generics to market including Ortofen, Ibuprofene, Ketamine, Parmidine and Etamsilate.


Dr Olga Shavrova

Innovation Advisor


Dr Olga Shvarova, D.Phil is the Innovation Advisor of NW PharmaTech, responsible for the direction of R&D and our innovation strategy.


Olga started to work with NW PharmaTech in June 2020 to help them meet regulatory requirements and joined the company after getting enthused with the company vision.


Olga is an Expert in Technology Transfer and Commercialisation with European Commission’s Joint Research Centre (JRC) and an Advisor for Asia-Pacific Economic Cooperation (APEC) Centre for Technology Transfer (APCTT). She has extensive experience in commercialisation strategy, IP protection and management, technology appraisal, and innovation processes and has held a number of senior posts in med-tech, M&A, corporate finance and private equity firms.


Olga holds a Doctorate Degree in Materials from the University of Oxford and has recently completed a course in Sustainable Finance from the Institute of Sustainability Leadership of the University of Cambridge.


Harriet Scorer

Medical & Regulatory Advisor


Harriet Scorer is the Medical & Regulatory Advisor of NW PharmaTech.


Harriet is an experienced pharmaceutical physician with over 30 years in the industry, working on OTC medicines and providing regulatory and medical advice to a range of companies, from start-ups to multinationals.


Harriet has worked extensively with MHRA and PAGB to develop switch guidelines and to facilitate the uptake of OTC medicines. She is Director of Scorer Health Ltd and Medical Affairs Specialist at OTC Experts.


Harriet is a graduate of Trinity College, Cambridge and has an MB BS from the University of London. She has a Diploma in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine.


Shankar Seetharaman

API Dossier Lead & Clinical Study QP


Shankar Seetharaman is the API Dossier Lead & Clinical Study QP of NW PharmaTech.


Shankar has over 20 years international experience at major pharmaceutical companies covering Quality Control, QA management, Quality and Regulatory Affairs. He specializes in quality systems, auditing, validation and contractor management, especially for companies in the early phases of development.


Shankar has helped to qualify numerous PET centers and their FDG production facilities across Europe and served as visiting lecturer at King’s College London.


Shankar holds a PhD in Pharmacology from the University of Cambridge, a Masters of Science Degree in Industrial Pharmaceutical Studies from the University of Brighton, as well as a Bachelors of Science Degree in Biochemistry from the N.E.S.C.O.T in Surrey.


Shankar is a Chartered Quality Professional, Member of the Chartered Quality Institute and Fellow of the Royal Society of Biology. He is also qualified as a Market Research Quality Analyst.



Our Partners

We are powered by a passionate team and partners - spanning prestigious learnings institutions, R&D companies, and clinical centres - all dedicated to unlocking the potential therapeutic benefits of nature, for a longer and healthier life.




We aim to achieve this with scientific rigour and an evidence-based approach, utilising the latest technologies that are emerging in the pharmaceutical sector in pre-clinical development, clinical validation, drug delivery mechanisms and medical Artificial Intelligence.


0203 693 3791


Beaufort Gardens
London SW3 1PW
United Kingdom